Publications by authors named "Cunyu Feng"
Article Synopsis
- Non-alcoholic fatty liver disease is a leading cause of chronic liver issues, and GPR40 is identified as a possible therapeutic target for related metabolic disorders.
- The study assessed a new GPR40 agonist, SZZ15-11, in diet-induced obese mice and HepG2 cells, observing significant reductions in hyperglycaemia, hyperlipidaemia, triglycerides, and cholesterol levels.
- SZZ15-11 was shown to enhance AMPK activity through cAMP accumulation, which is linked to the regulation of lipid metabolism, suggesting its potential benefits in treating fatty liver disease.
Background: L. (Sangzhi) alkaloid (SZ-A) is a new antidiabetic drug approved by the China National Medical Products Administration in 2020. Diabetic nephropathy (DN) is a common diabetic complication and an important cause of morbidity and mortality in patients with diabetes.
View Article and Find Full Text PDFVoglibose is an α-glycosidase inhibitor that improves postprandial hyperglycemia and increases glucagon-like peptide-1 (GLP-1) secretion in patients with type 2 diabetes. Recently, there has been increasing interest in the anti-inflammatory effects of voglibose on the intestine, but the underlying mechanism is not clear. This study evaluated the effects and mechanisms of voglibose on glycemic control and intestinal inflammation.
View Article and Find Full Text PDF